PMPrashant Nanasaheb Mohite

Prashant Nanasaheb Mohite

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Prashant Nanasaheb Mohite has a total of 369 co-authors. Here are the top co-authors by number of shared publications:

  • Bartlomiej Zych

    Royal Brompton and Harefield NHS Foundation Trust Hill End Road, Harefield, Uxbridge, London, UB9 6JH

    39 shared publications
  • Anton Sabashnikov

    Department of Cardiothoracic Surgery, University Hospital Cologne, 50937 Cologne, Germany

    32 shared publications
  • Anton Sabashnikov

    Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton & Harefield NHS Foundation Trust, Harefield Hospital, London, UK

    31 shared publications
  • Andre R. Simon

    Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Harefield Hospital, Royal Brompton and Harefield NHS Foundation Trust, London, UK

    30 shared publications
  • Nikhil P. Patil

    Heart and Vascular Institute, Penn State Milton S. Hershey Medical Center, Penn State College of Medicine, Hershey, Pennsylvania

    29 shared publications
  • André R. Simon

    Department of Cardiothoracic Transplantation and Mechanical Circulatory Support Harefield Hospital, Harefield, Uxbridge UK

    28 shared publications

Latest Publications

  • The United Kingdom National Programme of DCD heart transplantation: Timings, techniques, feasibility, and outcomes with abdominal normothermic regional perfusion

    by Karim Morcos, Lewis Simmonds, Sally Rushton, Rachel Hogg, Simon Messer, Debbie Macklam, Mubbasher Husain, Stephen Large, Steven Tsui, Pradeep Kaul, et al.


  • The United Kingdom’s experience of controlled donation after circulatory death direct procurement of lungs with concomitant abdominal normothermic regional perfusion with an analysis of short-term outcomes

    by Luke John Lloyd Williams, Rachel Hogg, Miguel Angel Reyes Roque, Sarah Beale, Mubassher Husain, Anand Jothidasan, Bart Zych, Vicky Gerovasili, Pradeep Kaul, Steven Tsui, et al.


  • Sternal sparing bilateral symmetrical thoracotomy for implantation of left ventricular assist device

    by Prashant Nanasaheb Mohite, Mubassher Husain, Maria Monteagudo-Vela, Kabeer Umakumar, Diana Garcia Saez, Anand Jothidasan, Andre R Simon

    Reopening the chest in patients with left ventricular assist devices at the time of a heart transplant is challenging due to adhesions and the possibility of injury to vital structures. The sternal sparing bilateral thoracotomy approach utilized to implant a left ventricular assist device minimizes the chances of such injuries and offers a cosmetically better outcome. We demonstrate a procedure for implanting a left ventricular assist device in a 54-year-old man diagnosed with dilated cardiomyopathy who suffered rapid decompensation despite maximum medical therapy.


  • Open Access

    Introductory Chapter: Basics of Cystic Fibrosis

    by Prashant N. Mohite, Vicky Gerovasili

    Open access peer-reviewed chapter

  • Open Access

    Lung Transplantation in Patients with Cystic Fibrosis

    by Prashant N. Mohite, Kavita Dave, Anna Reed, André R. Simon

    Cystic fibrosis (CF) is one of the most common indications for lung transplant (LTx) and nearly one-third of the LTx worldwide are performed in people with CF (PwCF). Due to vast developments in diagnostic modalities, antibiotic therapies, and management of associated comorbidities in dedicated and experienced centres, over the past few decades, more PwCF are reaching adulthood than ever before. This has increased the burden on transplant programs particularly in a universal donor shortage scenario. To improve the donor pool a diligent and proactive donor care management, acceptance of marginal organs and utilisation of ex-vivo lung perfusion systems for organ preservation, assessment, and improvement is being advocated widely. LTx is not a readily available therapy and the average waiting time is 18 months in the UK. Therefore, it is essential that PwCF are referred for LTx assessment when their disease is stable, before respiratory deterioration leads to overall deconditioning of the patients. Once listed for LTx, it is crucial to control waiting list mortality by prioritising rapidly deteriorating patients through schemes like the lung allocation score, national urgent and super-urgent waiting lists, and institutional highlighting of deteriorating patients that do not meet other urgent criteria. LTx in PwCF is challenging due to colonisation of the respiratory tract with multi-drug resistant organisms, associated comorbidities such as diabetes, liver disease, gastro-oesophageal reflux, and distal intestinal obstruction syndrome (DIOS) and CF-specific technical difficulties (adhesions due to prior pneumothoraces or pleurodesis, or bronchial collaterals that increase surgical time). Hilar lymphadenopathy and bronchial collaterals may increase surgical time, organ ischemia time, intra and post-operative bleeding, and blood transfusions. Advances in immunosuppression, prophylactic anti-viral and anti-fungal therapies, early ambulation and rigorous physiotherapy, and meticulous postoperative follow up with spirometry, x-rays, and bronchoscopies to detect rejection at the early stage followed by its efficient treatment have helped to improve post-LTx survival in the CF patients. Constant development in the surgical field with adoption of off-pump transplantation, sternal sparing bilateral thoracotomy approach, and utilisation of mechanical circulatory assist as a bridge to transplant and as a support for primary graft failure strives for better outcomes. However, chronic lung allograft dysfunction, chronic refractory infections, malignancies, and CF associated comorbidities remain major determinants of post-LTx long term survival. Despite this, CF patients are often good candidates for re-do LTx with improving survival outcomes. In this chapter, we are compiling the different aspects of LTx in PwCF emphasising the advances in bridge to transplantation, the surgical approach, management of primary graft failure, and immunosuppression as well as complications post-transplant.

  • Ex vivo lung perfusion made easy

    by Prashant N Mohite, Kabeer Umakumar, Olaf Maunz, Anand Jothidasan, Bartlomiej Zych, Hassiba Smail, Diana Garcia Saez, Andre R Simon

    Ex vivo lung perfusion is an indispensable tool in the armamentarium of any lung transplant center. It helps to increase an already shrinking donor pool by offering a chance to assess suboptimal donor lungs in a systematic manner and improve them by treating them with low-molecular-weight perfusate. We offer a stepwise guide to carry out ex vivo lung perfusion on the donor lungs and criteria to accept them for transplants.


  • Utilization of extracorporeal membrane oxygenation in DCD and DBD lung transplants: a 2‐year single‐center experience

    by Davorin Sef, Alessandra Verzelloni Sef, Prashant Mohite, Ulrich Stock, Vladimir Trkulja, Binu Raj, Diana Garcia Saez, Balakrishnan Mahesh, Fabio De Robertis, Andre Simon

    Donation after circulatory death (DCD) has the potential to expand the lung donor pool. We aimed to assess whether DCD affected the need for perioperative extracorporeal membrane oxygenation (ECMO) and perioperative outcomes in lung transplantation (LTx) as compared to donation after brain death (DBD). All consecutive LTx performed between April 2017 and March 2019 at our tertiary centre were analysed. Donor and recipient preoperative characteristics, utilization of ECMO and perioperative clinical outcomes were compared between DCD and DBD LTx. Multivariate models (frequentist and Bayes) were fitted to evaluate an independent effect of DCD on the intra‐ and postoperative need for ECMO. Out of 105 enrolled patients, 25 (23.8%) were DCD LTx. Donors’ and preoperative recipients’ characteristics were comparable between the groups. Intraoperatively, mechanical circulatory support (MCS) was more common in DCD LTx (56.0% vs. 36.2%), but the adjusted difference was minor (RR=1.16, 95%CI 0.64‐2.12; p=0.613). MCS duration, first and second lung ischemia time were longer in the DCD group. Postoperatively, DCD recipients more commonly required ECMO (32.0% vs. 7.5%) and the difference remained considerable after adjustment for the pre‐ and intraoperative covariates: RR=4.11 (95%CI 0.95‐17.7), p=0.058, Bayes RR=4.15 (95%CrI 1.28‐13.0). Sensitivity analyses (two DCD‐DBD matching procedures) supported a higher risk of postoperative ECMO need in DCD patients. Incidence of delayed chest closure, postoperative chest drainage, and renal replacement therapy was higher in the DCD group. Early postoperative outcomes after DCD LTx appeared generally comparable to those after DBD LTx. DCD was associated with a higher need for postoperative ECMO which could influence clinical outcomes. However, as the DCD group had a significantly higher use of EVLP with more common ECMO preoperatively, this might have contributed to worse outcomes in the DCD group.


  • Use of oxygenator with short‐term ventricular assist devices

    by Prashant Mohite, Rita Garda, Kabeer Umakumar, Sundip Kaul, Nandor Marczin, Bartlomiej Zych, Diana Garcia‐Saez, Maria Monteagudo‐Vela, Balakrishnan Mahesh, Ulrich Stock, et al.

    Venoarterial extracorporeal membrane oxygenation (VA‐ECMO) serves as a conventional short‐term mechanical circulatory assist to support heart and lung functions. The short‐term ventricular assist devices (ST‐VAD) can, on the contrary, offer only circulatory support. A combination of VAD and oxygenator (Oxy‐VAD) could help overcome this potential disadvantage. This is a retrospective case note study of patients supported on ST‐VAD which required adding an oxygenator for extra respiratory support. The oxygenator was introduced in the ST‐VAD circuit, either on the left or the right side. Twenty‐two patients with the etiology of refractory cardiogenic shock in decompensation were supported on Oxy‐VAD between years 2009 and 2019 at tertiary care . All patients were classified into class‐I INTERMACS with a mean SOFA Score of 14 ± 2.58. 86.4% of patients were already on mechanical support pre‐ST‐VAD implant, 80% on VA‐ECMO. The BiVAD implant accounted for 63.6%, followed by LVAD and RVAD with 27.3% and 9.1%. Mean duration of the ST‐VAD was 8.5 days. The oxygenator was introduced in 14 RVAD and 8 LVAD circuits. The oxygenator was successfully weaned in 54.5% while ST‐VAD was explanted in 31.8%. Discharge to home survival was 22.7%. Oxy‐VAD proves a viable, and probably, a better option to VA‐ECMO in acute cardiorespiratory decompensation. It offers organ‐specific tailor‐made support to the right and/or left heart and/or lungs. While on Oxy‐VAD support, each organ performance can be assessed independently, and the assistance of the specifically improved organ can be weaned off without discontinuing the support for the rest.


  • Bridge to heart transplantation using the Levitronix CentriMag short‐term ventricular assist device

    by Davorin Sef, Prashant Mohite, Fabio De Robertis, Alessandra Verzelloni Sef, Balakrishnan Mahesh, Ulrich Stock, Andre Simon


  • Open Access

    Isn’t Limb as Precious as Life?

    by Prashant N. Mohite, André R. Simon

    As utilisation of peripheral extra-corporeal life support (ECLS) is becoming clinical routine, its associated complications become more frequent. Distal limb perfusion in femoral cannulation remains one of the Achille’s heels in patients with peripheral ECLS. Unless detected early, limb ischemia may result in loss of limb and sometimes life. A protocol-based approach, precautions during ECLS implantation and explantation procedures and continuous monitoring of the limb during ECLS support are key elements in preventing this complication. Utilisation of a distal limb perfusion cannula helps in prevention as well as management of limb ischemia; however, it may sometimes cause more damage than help. Management and consequence of limb ischemia essentially depends on its severity at the time of detection as well as time of intervention. This chapter offers a brief review of the burden of limb ischemia, means to prevent and approaches to manage it.